Trial · NCT07880678
Risk Stratification for Adverse Events in End-Stage Liver Disease
NCT07880678, Not yet recruiting, The Second Affiliated Hospital of Chongqing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Risk Stratification for Adverse Events in End-Stage Liver Disease. Trials, record NCT07880678. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880678
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Risk Stratification for Adverse Events in End-Stage Liver Disease
- NCT number
- NCT07880678
- Status
- Not yet recruiting
- Enrollment
- 2,235 participants, estimated
- Lead sponsor
- The Second Affiliated Hospital of Chongqing Medical University
- Conditions
- Decompensated Cirrhosis
- Interventions
- Routine Clinical Care with Biospecimen Collection and Free MRE Testing
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Further Decompensation at 1 Year | Within 12 months after enrollment | Further decompensation is defined per Baveno VII criteria as any of the following: (1) occurrence of a second portal hypertension-related decompensating event (ascites, variceal bleeding, or hepatic encephalopathy); (2) recurrent variceal bleeding, recurrent ascites requiring ≥3 large-volume paracenteses within 1 year, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis, and/or hepatorenal syndrome-acute kidney injury; or (3) development of ascites or hepatic encephalopathy after surgery in patients with variceal bleeding as the sole prior event. |
| Secondary | 6-Week Liver-Related Mortality Rate | Within 6 weeks after enrollment | Death directly attributed to liver disease or its immediate complications (e.g., liver failure, variceal rebleeding, infections). |
| Secondary | 1-Year Liver-Related Mortality Rate | Within 12 months after enrollment | Death directly attributed to liver disease or its immediate complications (e.g., liver failure, variceal rebleeding, infections). |
| Secondary | Incidence of Liver Failure at 1 Year | Within 12 months after enrollment | Defined per 2023 EASL ACLF criteria: total bilirubin ≥12 mg/dL plus any of: (1) INR ≥2.5; (2) serum creatinine ≥2.0 mg/dL or need for RRT; (3) hepatic encephalopathy ≥ grade 3 (West Haven); (4) need for vasopressors; or (5) PaO₂/FiO₂ ≤200 or SpO₂/FiO₂ ≤214. |
| Secondary | Recompensation Rate at 2 Years | Within 24 months after enrollment | Per Baveno VII consensus: sustained resolution of ascites, hepatic encephalopathy, and variceal bleeding with stable improvement in liver function for ≥12 months after etiological treatment. |
| Secondary | Recompensation Rate at 3 Years | Within 36 months after enrollment | Per Baveno VII consensus: sustained resolution of ascites, hepatic encephalopathy, and variceal bleeding with stable improvement in liver function for ≥12 months after etiological treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880678
GET https://conductscience.org/api/trials/v1/NCT07880678/registered